Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Lee, Gregory; *
Affiliations: Andrology Laboratory, Department of Obstetrics and Gynaecology, The University of British Columbia, Vancouver, BC, Canada
Correspondence: [*] Corresponding author: Andrology laboratory, Rm D403A, UBC Center for Reproductive Health, 4500 Oak Street, Vancouver, BC V6H 3N1, Canada. Tel.: +1 778 322 4651; E-mails: cyglee@yahoo.com; andr@interchange.ubc.ca.
Note: [1] United States Patent Number 5,650,291, issued on July 22, 1997.
Note: [2] G. Lee, B. Ge. Cancer Cell expressions of immunoglobulin heavy chains with unique carbohydrate-associated biomarker (submitted for publication).
Abstract: Background:RP215 was the first generated monoclonal antibody which recognizes specifically carbohydrate-associated epitope(s) localized in the variable region of the cancer cell-expressed immunoglobulin heavy chains, designated in general as CA215. Clinical evaluations were performed to assess if RP215 can be utilized in immunoassays to determine serum levels of CA215 among ovarian or cervical cancer patients for monitoring purposes. Methods:By using immunoassays, serum CA215 levels were determined from cervical or ovarian cancer patients and evaluated based on their respective clinical stages as well as the conditions of clinical treatments. Results:Multi-center clinical trials were performed with frozen serum specimens of patients with ovarian or clinical cancers to determine the efficacy of RP215-based immunoassays. In the case of ovarian cancer, CA215 immunoassay kit has a sensitivity of 46–68% as compared to 46–70% for that of the corresponding CA125 kit. When both markers were combined for simultaneous monitoring of cancer patients, the sensitivity could be as high as 72–87%. Further analysis revealed that serum CA215 levels among cancer patients are well correlated with stages of tumor progression as well as surgical or radio/chemo treatments. Conclusions:The results of these multi-center clinical studies suggest that CA215 is a suitable pan cancer marker for the monitoring of ovarian/cervical cancers and maybe of several others which express CA215 and can be detected in human circulations.
Keywords: CA215, pan cancer marker, cancer cell-expressed immunoglobulins, carbohydrate-associated epitope, RP215 monoclonal antibody, monitoring of human cancers, in vitro diagnostics
DOI: 10.3233/CBM-2009-0610
Journal: Cancer Biomarkers, vol. 5, no. 3, pp. 137-142, 2009
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl